Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 10:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 709 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Decadron Clear all

Conditions: DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma
Interventions: Bortezomib, Dexamethasone, Elotuzumab, Laboratory Biomarker Analysis, Lenalidomide; Drug · Biological · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2025
U.S. locations: 417
States / cities: Anchorage, Alaska • Little Rock, Arkansas • Burbank, California + 261 more

Conditions: Ocular Disease Requiring Surgery
Interventions: DEXTENZA®; Drug
Lead sponsor: Nathan Steinle; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 3
States / cities: Paso Robles, California • San Luis Obispo, California • Santa Maria, California

Conditions: Post-Surgical Ocular Pain, Post-Surgical Ocular Inflammation
Interventions: Dextenza 0.4Mg Ophthalmic Insert; Drug
Lead sponsor: Kerry Assil, MD; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Beverly Hills, California

Conditions: Recurrent Plasma Cell Myeloma
Interventions: Dexamethasone, Laboratory Biomarker Analysis, Lenalidomide, Pharmacological Study, R-(-)-Gossypol Acetic Acid; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Diffuse Large B-cell Lymphoma
Interventions: CC-5013 (lenalidomide), dexamethasone; Drug
Lead sponsor: Celgene Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 19
States / cities: Glendale, Arizona • Beverly Hills, California • Miami, Florida + 15 more

Conditions: Multiple Myeloma
Interventions: Autologous peripheral blood stem cell transplant, Lenalidomide, Dexamethasone, Stem cell collection, Melphalan, G-CSF, Cyclophosphamide, Mesna; Procedure · Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Nasopharyngeal Carcinoma
Interventions: Docetaxel, Carboplatin, Dexamethasone, EBV-specific cytotoxic T lymphocytes, G-CSF or Peg-GCSF; Drug · Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 10 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 3
States / cities: Houston, Texas

Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions: Bortezomib, Daratumumab, Dexamethasone, Ixazomib, Quality-of-Life Assessment; Drug · Biological · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Retinal Vein Occlusions
Interventions: Not listed
Lead sponsor: Barnes Retina Institute; Other
Eligibility: 21 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Plasma Cell Myeloma, Plasmacytosis, Recurrent Plasma Cell Myeloma, Smoldering Plasma Cell Myeloma
Interventions: Melphalan, Bortezomib, Dexamethasone, Autologous Transplant; Drug · Procedure
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 70 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Post Minimally Invasive Thorascopic Surgical Pain
Interventions: Bupivacaine and Dexamethasone, Placebo; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma
Interventions: Dexamethasone, Laboratory Biomarker Analysis, Lenalidomide, Thalidomide; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2026
U.S. locations: 138
States / cities: Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 115 more

Conditions: Multiple Myeloma
Interventions: Clarithromycin, Lenalidomide, Dexamethasone; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 65 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 2
States / cities: Aurora, Colorado • New York, New York

Conditions: Lymphoblastic Lymphoma
Interventions: Vincristine, Radiation Therapy, Daunomycin, L-Asparaginase, Cytarabine, Methotrexate, Mercaptopurine, Etoposide, Cyclophosphamide, Prednisone, Dexamethasone; Drug · Procedure
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Not listed
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 2004
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Vitreo-Retinal Surgery
Interventions: Dextenza 0.4Mg Ophthalmic Insert, Topical Prednisolone; Drug
Lead sponsor: Patrick R. Oellers, MD; Network
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Liverpool, New York

Conditions: Multiple Myeloma
Interventions: MK-3475, Pomalidomide, Dexamethasone; Drug
Lead sponsor: Ashraf Badros; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Multiple Myeloma
Interventions: Amrubicin, Lenalidomide, Dexamethasone, Aspirin, Pegfilgrastim; Drug
Lead sponsor: Michaela Liedtke; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Stanford, California

Conditions: Carcinoma, Small Cell, Lung Cancer, Small Cell Lung Cancer
Interventions: M7824, Topotecan, Temozolomide, EKG, CT scan, PET scan, Acetaminophen, Antihistamines, Diphenhydramine, Dexamethasone, Epinephrine; Drug · Diagnostic Test
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Multiple Myeloma
Interventions: One Autologous Transplant, Non-Myeloablative Allogeneic Transplant, Second Autologous Transplant, Thalidomide, Dexamethasone, Observation; Procedure · Drug · Behavioral
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Up to 70 Years
Enrollment: 710 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2013
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 28 more

Conditions: Macular Edema
Interventions: Updated DEX PS DDS Applicator, Approved DEX PS DDS Applicator, Dexamethasone; Device · Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 7
States / cities: Glendale, California • North Dartmouth, Massachusetts • Independence, Missouri + 4 more

Conditions: Myeloma
Interventions: Palifermin, Dexamethasone, Gemcitabine, Busulfan, Melphalan, Stem Cell Transplant, G-CSF; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Locally Advanced Malignant Neoplasm, Breast Cancer
Interventions: Propranolol, DOT imaging, Paclitaxel, Nab-paclitaxel, Trastuzumab, Pertuzumab, Doxorubicin, Cyclophosphamide, Surgery, Premedication, Anti-nausea therapy, Pegfilgrastim; Drug · Other · Procedure
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Dry Eye Syndromes
Interventions: Dextenza 0.4Mg Intracanalicular Insert, Over the counter Artificial tears; Drug · Other
Lead sponsor: The Eye Centers of Racine and Kenosha; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Racine, Wisconsin

Conditions: Leukemia
Interventions: filgrastim, asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, etoposide, idarubicin, leucovorin calcium, mercaptopurine, methotrexate, prednisone, vincristine sulfate, radiation therapy; Biological · Drug · Radiation
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 17 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2007
U.S. locations: 51
States / cities: Tucson, Arizona • Palo Alto, California • Sacramento, California + 44 more

Search by objective public record fields.

S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma

INtravitreal and Aqueous Dexamethasone Levels After DEXtenza

Dextenza Within Upper Lid Canaliculus Compared With Lower Lid Canaliculus Following Bilateral Cataract Extraction Surgery With PCIOL.

Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple Myeloma

A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma

Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes

Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Anatomic Outcomes Following Ozurdex Injections

Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

The Effect of Dexamethasone on the Duration and Functionality of Bupivacaine Intercostal Nerve Blockade

Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma

BiRd vs. Rd as Initial Therapy in Multiple Myeloma

Treatment for Patients With Stage III or IV Non-Hodgkin Lymphoma

DEXTENZA for the Treatment of Postoperative Pain and Inflammation Following Vitreo-retinal Surgery

1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma

Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma

M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers

Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)

A Study to Evaluate an Updated Dexamethasone Intravitreal (Into the Eye) Applicator in Adult Participants With Macular Edema Due to Diseases of the Retina

High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma

Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

ACCURATE Study for Subjects With Dry Eyes

Combination Chemotherapy in Treating Children With Very High Risk Acute Lymphocytic Leukemia